Drugs / I131
I131
Trials 0
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05668962 Background | Mar 2023 → Mar 2025 overdue | thyroid gland follicular carcinoma, thyroid gland papillary carcinoma | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02418247 Comparator | May 2013 → Dec 2017 | thyroid tumor | National Cancer Center, Korea | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05468554 Background | Nov 2022 → Apr 2026 | thyroid cancer | Medical University of Bialystok | Unknown | No outcome recorded |
| Phase 3 | NCT04290663 Comparator | Mar 2020 → Feb 2031 expected | thyroid cancer | Centre Francois Baclesse | Recruiting | No outcome recorded |
| Phase 3 | NCT01837745 Comparator | May 2013 → Apr 2022 overdue | differentiated thyroid carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02114619 Comparator | May 2013 → Dec 2014 | Graves disease | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | I131 | “Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation” NCT04290663 ↗ |
| Known as | I-131 NaI | “I-131 NaI” NCT05668962 ↗ |
| Known as | iodine-131 | “postoperative administration of radioiodine (iodine-131) is controversial in the absence of demonstrated benefits.” PMID 35263518 ↗ Mar 2022 |
| Known as | Radioactive iodine | “Radioactive iodine (RAI) administration is an effective and completely established treatment modality in hyperthyroidism including Graves' disease.” NCT02114619 ↗1“Radioactive iodine (I-131)” NCT05468554 ↗ |
| Known as | RAI | “Radioactive iodine (RAI) administration is an effective and completely established treatment modality in hyperthyroidism including Graves' disease.” NCT02114619 ↗ |
| Known as | Sodium Iodine I-131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05668962 ↗ |
| Modality | Other / unclassified | “Radioactive iodine (RAI) administration is an effective and completely established treatment modality” NCT02114619 ↗ |
| Route | Oral | “An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.” NCT01837745 ↗ |